RG6351 / Roche - LARVOL DELTA

The other mid-stage asset thrown on the scrap heap was an anti-Tie2 agonist dubbed RG6351. (FierceBiotech) - "Roche had been assessing the therapy in the eye disease diabetic macular edema (DME) as both a monotherapy and in combination with Eylea or Vabysmo."

Discontinued • Diabetic Macular Edema

THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov) - P1/2 | N=388 | Completed | Sponsor: Genentech, Inc. | Trial completion date: Apr 2027 ➔ Jun 2026 | Trial primary completion date: Apr 2027 ➔ May 2026 | Active, not recruiting ➔ Completed

Trial completion • Trial completion date • Trial primary completion date • Diabetic Macular Edema • Ophthalmology

THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov) - P1/2 | N=546 | Active, not recruiting | Sponsor: Genentech, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Diabetic Macular Edema • Ophthalmology

THAMES: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema (clinicaltrials.gov) - P1/2 | N=546 | Recruiting | Sponsor: Genentech, Inc.

New P1/2 trial • Diabetic Macular Edema • Ophthalmology